The average size (diameter, nm) of CCIONPs is 200.5 nm, which confirms that the prepared nanoparticles lie in the nanometer range, whereas, in the case of CNPs, it is shown that they are quite lower in size than CCIONPs.
On comparing the TEM image of CCIONPs with CNPs, it can be clearly demonstrated that CCIONPs comprise of core/shell structure with the homogenous incorporation of magnetite as a core of CCIONPs.
This local endothelial production, coupled to the vasodilator, anti-platelet and anti-leukocyte effects of CNP, imply it has the potential to exert a multi-pronged anti-atherosclerotic influence on the blood vessel wall.
We recommend that real-time QPCR data be treated with a high degree of caution and suggest that if it is used for the analysis of multi-allelic CNPs, that it is accompanied by independent genotyping measures such as MLPA or PRT.
Other advantages of using polyelectrolyte coating on CNPs is that it is to prevent biofouling of nanoparticles and preserve its catalytic nature.
If this therapeutic potential of CNP is to be harnessed, it is imperative that mechanisms underlying this unique pharmacodynamic profile are delineated.
Probably because CNP are hydrophobic and aggregate readily, it is difficult to disperse them in living organisms.
An innovative natriuretic peptide analogue called CNAAC (a new chimera peptide combining the C-terminus and ring of ANP with the N-terminus of CNP) was designed to determine whether it has any cardiovascular and renal effect.
It includes GALP, GAD1, CNP, CRFBP, GABRD, NPY, MERP and IRX2.
First, it calculates the raw CNP by counting reads in non-overlapping windows.
